argenx SE (Nasdaq: ARGX) provided an update to its Phase 1/2 clinical trial of ARGX-110 in cutaneous T-cell lymphoma and announced a proposed public offering of $150 million American Depositary Shares. Shares of the biopharmaceutical leaped $24.02 to close at $54.47.
argenx SE provided updated trial data
December 11, 2017 at 16:50 PM EST